Overview

Efficacy and Safety of Rivaroxaban in Acute Non-neoplastic Portal Vein Thrombosis in HCV

Status:
Completed
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
Portal vein thrombosis (PVT) in patients with liver cirrhosis may be due to neoplastic growth or non-neoplastic causes. - Treating PVT with anticoagulation in liver cirrhosis is difficult to be established but may be of great benefit in acute symptomatic PVT. - The ultimate goal is complete recanalization of the portal vein without inducing major bleeding, abnormal liver function tests or increased mortality.
Phase:
N/A
Details
Lead Sponsor:
Zagazig University
Treatments:
Rivaroxaban